The objective was to certify if the drug silybum could decrease the blood triglycerides level of hypertriglyceridemia patients, and how adverse reactions would be produced on their liver and renal function or elsewhere. A total of 80 cases of hypertriglyceridemia (TG≥2.50 mmol/L) with cardiac cerebral vascular disease, or hepatic disease from out-patient department or admitted patients, were given silybum 0.2 bid orally to 30 or/and 60 days. Their blood lipids, fast blood glucose, liver and renal function were checked before treatment and one/or two months after treatment. And what else adverse reactions happened after treatment, if any, were all recorded. 30 Days after drug administration, the blood TG level of 15 cases (27.3%) decreased by ≥40%, which is evident, and blood TG level of 27 cases (49.1%) decreased by ≥20% but less than 40%, which is effective. In 49 cases, 60 days after drug administration, 25 cases (51.0%) are evident, and 15 cases (30.6%) are effective. The total efficacy is 76.4% after one month and 81.6% after two months. There were a few decrease of the level of blood total cholesterol(TC) after treatment both after one or two months, but were not significant statistically(P>0.05), and there were evidently no significant difference of HDL-C or LDL-C between their levels after treatment and before treatment. There were not any adverse influence to liver or renal function, and fasting blood glucose, whenever after taking the drug one or two months;on the contrary, the drug can improve or even treat the abnormal liver function such as to decrease the elevated blood transaminase prominently. All patients hadn't any noxious adverse action to be recorded. Silybum can decrease the blood triglyceride level of hypertriglyceridemia patients, without any adverse influence to liver or kidney function, or other toxic action. And silybum can even improve or treat the abnormal liver function, to decrease abnormal elevated blood transaminase evidently, so that it could be suggested to be used as the first line drug to treat the hypertriglyceridemia.